Pitcher John D, Liu Tiffany, Prasad Pradeep S, Schwartz Steven D, Hubschman Jean-Pierre
Jules Stein Eye Institute, Department of Ophthalmology, University of California, David Geffen School of Medicine, Los Angeles, CA 90095-7000, USA.
Semin Ophthalmol. 2012 May-Jul;27(3-4):69-72. doi: 10.3109/08820538.2011.643272.
To evaluate the safety, functional, and anatomical outcomes of short-duration pattern scanning laser (PASCAL) macular photocoagulation in the treatment of macular edema related to branch retinal vein occlusion (BRVO).
Consecutive retrospective analysis of visual acuity (VA), optical coherence tomography (OCT), and adverse events from eyes treated with PASCAL macular photocoagulation for BRVO-related macular edema. Two-tailed paired t-tests were used to compare pre- and post-treatment VA and central retinal thickness (CRT).
A total of 35 eyes from 35 patients and 18 eyes from 18 patients met study criteria for VA and OCT analysis, respectively. All treatments were delivered with the same PASCAL photocoagulation unit. Mean laser settings were 133-µm spot size, 15-millisecond pulse duration, 250-mW power, and fluence of 29 J/cm(2) with an average of 1.4 treatments and 335 shots per patient. Adjunct treatment with intravitreal anti-VEGF injections and pan-retinal photocoagulation was administered in 27 and 16 eyes, respectively. At an average follow-up of 12 months (range 3-43 months) post-treatment, no laser-related ocular complications were observed. Visual acuity was not significantly changed (p = 0.07), although the number of patients with vision better than 20/40 doubled following treatment. CRT was reduced by an average of 110 µm (p = 0.0009).
Short-duration PASCAL macular photocoagulation appears to be a safe treatment option that results in significant anatomical improvement in macular edema related to BRVO.
评估短疗程模式扫描激光（PASCAL）黄斑光凝治疗视网膜分支静脉阻塞（BRVO）相关黄斑水肿的安全性、功能及解剖学转归。
对接受PASCAL黄斑光凝治疗BRVO相关黄斑水肿的患者的视力（VA）、光学相干断层扫描（OCT）及不良事件进行连续回顾性分析。采用双尾配对t检验比较治疗前后的VA及中央视网膜厚度（CRT）。
分别有35例患者的35只眼和18例患者的18只眼符合VA和OCT分析的研究标准。所有治疗均使用同一台PASCAL光凝设备。平均激光参数为光斑大小133 µm、脉冲持续时间15毫秒、功率250 mW、能量密度29 J/cm²，每位患者平均治疗1.4次，每次335击。分别有27只眼和16只眼接受了玻璃体腔抗VEGF注射及全视网膜光凝辅助治疗。治疗后平均随访12个月（范围3 - 43个月），未观察到与激光相关的眼部并发症。视力虽无显著变化（p = 0.07），但治疗后视力优于20/40的患者数量翻倍。CRT平均降低110 µm（p = 0.0009）。
短疗程PASCAL黄斑光凝似乎是一种安全的治疗选择，可使BRVO相关黄斑水肿在解剖学上得到显著改善。
